Durvalumab

Durvalumab (デュルバルマブ)

一行要約

Anti-PD-L1 IgG1κ mAb (Fc engineered、ADCC なし)。PACIFIC で Stage III unresectable NSCLC CRT 後 consolidation (OS HR 0.68、5-yr OS 43%) を確立し、Stage III 治療の paradigm を変革。CASPIAN で ES-SCLC 1L IO+chemo (OS HR 0.73)、AEGEAN で perioperative NSCLC (EFS HR 0.68)、ADRIATIC で LS-SCLC CRT 後 consolidation の活性を示し、stage I–IV NSCLC + SCLC (ES / LS) の全領域で承認を持つ thoracic oncology で最も幅広い PD-(L)1 portfolio を有する agent。最近では肝細胞癌 (HIMALAYA、tremelimumab 併用)、胆道癌 (TOPAZ-1)、子宮内膜癌 (DUO-E) にも展開し、PD-L1 経路 backbone として横断的に展開中。

主要エビデンス

Stage III unresectable NSCLC — PACIFIC (pivotal)

PACIFIC は 713 例の definitive CRT 後 stage III unresectable NSCLC を対象に durvalumab 12 ヶ月 consolidation vs placebo を比較し、PFS 16.8 vs 5.6 ヶ月 (HR 0.52、Antonia et al. NEnglJMed 2017)、OS HR 0.68 (Antonia et al. NEnglJMed 2018) の primary 達成。長期 follow-up (Faivre-Finn et al. JThoracOncol 2021) で 4-yr OS 49.6% vs 36.3%、5-yr OS 42.9% vs 33.4% の durable plateau を確認、Stage III 治療の “PACIFIC regimen” (cCRT → durvalumab) として global standard を確立した。Subsequent subgroup 解析では CRT 14 日以内の早期開始 (Faivre-Finn et al. LungCancer 2021) で benefit 増強、post-progression IO 影響補正後も OS benefit 維持 (Ouwens ELCC 2019)。EGFR-mut subgroup では benefit 限定的 (Aredo et al. JThoracOncol 2021) で、現在は LAURA に基づき osimertinib consolidation を推奨。

ES-SCLC 1L — CASPIAN

Paz-Ares et al. Lancet 2019 が ES-SCLC 1L で durvalumab + platinum/etoposide vs platinum/etoposide alone の OS 13.0 vs 10.3 ヶ月 (HR 0.73) を示し、IMpower133 (atezolizumab + carbo/etoposide) と双璧の ES-SCLC IO + chemo standard を確立。Tremelimumab 上乗せ群は Goldman et al. LancetOncol 2021 で OS HR 0.82 (CI 跨ぎ) と benefit 不確定で、最終的に durvalumab 単剤 + chemo が承認された。Cisplatin と carboplatin の選択を許容する flexible design が CASPIAN の特徴で、IMpower133 (carbo 限定) と差別化された。

Perioperative NSCLC — AEGEAN

Heymach et al. NEnglJMed 2023 (AEGEAN) は resectable stage IIA–IIIB (N2) NSCLC 740 例で perioperative durvalumab + neoadjuvant chemo → surgery → adjuvant durvalumab vs placebo + chemo を比較し、pCR 17.2% vs 4.3%、MPR 33.3% vs 12.3%、EFS HR 0.68 を達成。CheckMate 77T (nivolumab) / KEYNOTE-671 (pembrolizumab) と並ぶ perioperative IO 三本柱の一つを構成。EGFR / ALK 陽性は除外され、driver-positive 例は ADAURA / ALINA を選択する戦略が形成されている。

LS-SCLC consolidation — ADRIATIC (SCLC 初)

ADRIATIC (Cheng et al. NEnglJMed 2024) は limited-stage SCLC 730 例で cCRT 後の durvalumab ± tremelimumab vs placebo を比較し、OS HR 0.73 (55.9 vs 33.4 ヶ月)、PFS HR 0.76 を示し、SCLC 初の consolidation IO として歴史的意義を持つ。LS-SCLC は 30 年以上 cCRT のみが standard だったが、ADRIATIC により stage III NSCLC PACIFIC に類似した paradigm shift が SCLC でも実現した。

1L metastatic NSCLC — POSEIDON

POSEIDON (Johnson et al. CancerDiscov 2022 JCO) は metastatic NSCLC 1L で durvalumab + tremelimumab + chemo (5 cycles) vs durvalumab + chemo vs chemo の三群を比較し、durvalumab + treme + chemo arm が OS HR 0.77 を示したが、PD-1-inhibitor (pembrolizumab / nivolumab + ipilimumab) の dominance により 1L metastatic では niche choice。STK11 / KEAP1 mut subgroup で durvalumab + tremelimumab + chemo が benefit を示すデータがあり (Pore et al. CancerDiscov 2021)、biomarker-driven 適応の探索が進む。

Liquid biopsy / MRD biomarker

PACIFIC 後の MRD ctDNA 動態は consolidation IO benefit を予測することが Moding et al. NatCancer 2020 で示され、Xia et al. ClinCancerRes 2022、Gale et al. AnnOncol 2022 が perioperative MRD framework を補強。Durvalumab を MRD-guided escalation/de-escalation に組み込む戦略が研究されている。

メカニズム

• PD-L1 blockade: PD-L1 に高親和性で結合し PD-1 / B7.1 (CD80) との相互作用を遮断 → CD8+ T cell exhaustion 解除
• Fc engineering: IgG1 Fc CH2 domain に triple mutation (L234F / L235E / P331S) → FcγR / C1q 結合消失 → ADCC / CDC なし。PD-L1+ 正常組織 (胎盤等) への cytotoxicity を回避
• PD-L1 vs PD-1 阻害の差異: PD-L1 抗体は PD-L1/B7.1 共阻害 → APC–T cell co-stimulation の restoration を含む。一方 PD-1 抗体は PD-L2 も遮断
• CRT synergy (PACIFIC rationale) : 放射線が tumor neoantigen exposure / DNA damage → cGAS-STING 活性化 / ICD → immunogenic priming → durvalumab で T cell reactivation。CRT 後の “window of opportunity” を活用
• STK11/KEAP1 resistance: STK11 LOF が PD-L1 / IFN-γ シグナル低下、neutrophil-driven immune evasion を介した resistance (Pore et al. CancerDiscov 2021)

臨床位置づけ

• Stage III unresectable NSCLC: PACIFIC に基づき cCRT 後 durvalumab consolidation 12 ヶ月が global standard。PD-L1 ≥1% で推奨 (日本では TPS 不問で承認)
• Perioperative resectable NSCLC: AEGEAN に基づき neoadjuvant chemo + durvalumab → surgery → adjuvant durvalumab。CheckMate 77T / KEYNOTE-671 と competitive、driver-negative で選択
• ES-SCLC 1L: CASPIAN に基づき durvalumab + platinum/etoposide が standard (IMpower133 と双璧)。Maintenance durvalumab を progression まで継続
• LS-SCLC consolidation: ADRIATIC に基づき cCRT 後 consolidation — SCLC 初の consolidation IO として SCLC 治療体系を拡張
• 1L metastatic NSCLC: POSEIDON で承認あるが niche、STK11/KEAP1 mut で treme 追加検討
• EGFR/ALK NSCLC: PACIFIC EGFR-mut subgroup で benefit 限定 (Aredo JTO 2021) → LAURA osimertinib に置換
• 毒性: Pneumonitis (Stage III cCRT 後で要注意、grade 3+ 約5%)、甲状腺機能障害、肝炎、大腸炎、内分泌障害。全般に anti-PD-1 と同等の irAE profile

Open Questions

• Stage III IO duration: PACIFIC 12 ヶ月固定 vs ctDNA-guided 短縮 / 延長
• EGFR/ALK Stage III: LAURA osimertinib vs durvalumab → osimertinib sequence
• ES-SCLC PD-L1 / inflamed subset: Durvalumab vs atezolizumab の患者選択 biomarker
• Perioperative driver-negative: AEGEAN vs CheckMate 77T vs KEYNOTE-671 の clinical positioning (cross-trial)
• STK11/KEAP1 個別化: Durvalumab + tremelimumab + chemo の biomarker-stratified study
• Pneumonitis 管理: Stage III CRT 後 grade ≥2 pneumonitis と durvalumab discontinuation 影響

重要論文 Top 10

1. ★★★★★ Antonia et al. NEnglJMed 2018 — PACIFIC OS — Stage III paradigm shift
2. ★★★★★ Paz-Ares et al. Lancet 2019 — CASPIAN — ES-SCLC IO+chemo standard
3. ★★★★ Heymach et al. NEnglJMed 2023 — AEGEAN — Perioperative IO 確立
4. ★★★★ Faivre-Finn et al. JThoracOncol 2021 — PACIFIC 4-5 yr OS durability
5. ★★★★★ Antonia et al. NEnglJMed 2017 — PACIFIC primary — PFS HR 0.52

関連エンティティ

• Drug class: PD-L1-inhibitor
• 標的: PD-L1
• 併用相手: Platinum-chemotherapy, Etoposide, Tremelimumab (CTLA-4-inhibitor)
• 競合: PD-1-inhibitor (Pembrolizumab, Nivolumab), Atezolizumab
• 試験: PACIFIC, CASPIAN, AEGEAN, ADRIATIC
• Concept: irAE
• ドメイン: lung-cancer-treatment

関連論文

直近 30 件のみ表示中 (関連 267 件)。 全件は MOC ページ または Obsidian (source Markdown) から辿れます。

Basic-Brain metastasis

• Chen et al. FrontOncol 2026 — Stereotactic radiotherapy for brain metastases indications, dose fractionation, technological innovations, and evolving
• Lu et al. JClinOncol 2026 — Multicenter cohort study of original or substitute systemic therapy with or without brain radiotherapy for

Basic-Immunotherapy

• Kamigaichi et al. CancerImmunolImmunother 2026 — Immunological impact of tumor-draining lymph node dissection on systemic th1-like CD4+ T cells in patients with
• Wang et al. Cell 2026 — A blood-brain barrier-like vascular gate limits immunotherapy efficacy in neuroendocrine cancers
• Smesseim et al. FrontMed(Lausanne) 2026 — Defining the abscopal effect in non-small cell lung cancer in the era of immunotherapy and lung ablation treatment a

Basic-Liquid-biopsy

• Cai et al. JImmunotherCancer 2026 — Neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA-IIIB non-small cell lung cancer integrated
• Horndalsveen et al. JThoracOncol 2026 — ctDNA based MRD detection in stage III NSCLC treated with chemoradiotherapy and durvalumab

Basic-Neutrophil and myeloid cell

• Lin et al. CancerDiscov 2026 — Arachidonic acid metabolism in PMN-MDSCs suppresses antitumor capacity of T cells in KRAS-mutant cholangiocarcinoma
• Wu et al. FrontImmunol 2026 — Tumor-associated neutrophils in pancreatic ductal adenocarcinoma mechanisms and therapeutic targeting

Basic-Oncogene and genetics

• Yap et al. Cell 2026 — Targeting genomic instability in cancer

Basic-Others

• Osarogiagbon et al. AmSocClinOncolEducBook 2026 — Optimal use of targeted therapy and immunotherapy in early-stage, resectable non-small cell lung cancer
• ODwyer et al. BMJOncol 2026 — Treatment of oligometastatic lung cancers new data, new drivers, new approaches
• De et al. NatMed 2026 — Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER

Clinical-NSCLC-Driver negative

• Li et al. FrontImmunol 2026 — The application and challenges of immune checkpoint inhibitors in lung cancer therapy
• Chaft et al. JAMA 2026 — Adjuvant nivolumab vs observation in resected Non-Small cell lung cancer
• Socinski et al. JAMAOncol 2026 — Tiragolumab plus atezolizumab and chemotherapy for advanced nonsquamous non-small cell lung cancer the phase 3
• Provencio et al. NatCancer 2026 — Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC phase 3

Clinical-NSCLC-EGFR

• Niu et al. FrontImmunol 2026 — Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following
• Okamoto et al. LungCancer 2026 — Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and

Clinical-Novel modalities

• Jee et al. CancerDiscov 2026 — Deconvolving SARS-CoV-2 mRNA vaccine impact on immunotherapy-related survival
• Li et al. MolCancer 2026 — Antibody-drug conjugates in breast cancer from mechanism to revolutionizing clinical practice

Clinical-Others

• Li et al. FrontImmunol 2026 — Effect of histology on the efficacy of first-line immune checkpoint inhibitors in advanced non-small cell lung cancer a
• Zhu et al. IntJRadiatOncolBiolPhys 2026 — Low-dose SBRT-based radiotherapy followed by pembrolizumab and chemotherapy for potentially resectable NSCLC A phase ib
• Naing et al. JImmunotherCancer 2026 — Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-pd-1
• Baramidze et al. JThoracOncol 2026 — Cemiplimab plus chemotherapy versus chemotherapy in advanced NSCLC 5-year results from phase 3 EMPOWER-lung 3 part 2

Clinical-SCLC

• Guan et al. CritRevOncolHematol 2026 — Overcoming immunotherapy resistance in extensive-stage small cell lung cancer insights into mechanisms and therapeutic
• Dai et al. CurrTreatOptionsOncol 2026 — Addressing unmet needs in the management of small cell lung cancer treatment of brain metastases, quality of life, and
• Zhang et al. FrontImmunol 2026 — First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain
• Liu et al. JAMAOncol 2026 — First-line serplulimab in extensive-stage small cell lung cancer secondary analysis of the ASTRUM-005 phase 3
• Byers et al. NatMed 2026 — SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors a phase 1 trial